ICU Medical Inc: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 9, 2018 and accepted by EDGAR at Aug 9, 2018, 16:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2018-04-01 to 2018-06-30 | $151.8m | us-gaap:GrossProfit |
| Gross profit | 6 months2018-01-01 to 2018-06-30 | $300.8m | us-gaap:GrossProfit |
| Research and development | 3 months2018-04-01 to 2018-06-30 | $13.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-01-01 to 2018-06-30 | $26.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-04-01 to 2018-06-30 | $83.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2018-01-01 to 2018-06-30 | $170.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-04-01 to 2018-06-30 | $30.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | $32.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-04-01 to 2018-06-30 | $130.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2018-01-01 to 2018-06-30 | $265.0k | us-gaap:InterestExpense |
| Income tax | 3 months2018-04-01 to 2018-06-30 | −$1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2018-01-01 to 2018-06-30 | −$2.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 6 months2018-01-01 to 2018-06-30 | $35.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | $1.44 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | $1.67 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-04-01 to 2018-06-30 | $1.53 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2018-01-01 to 2018-06-30 | $1.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-04-01 to 2018-06-30 | 21,569,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2018-01-01 to 2018-06-30 | 21,536,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | $59.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2018-01-01 to 2018-06-30 | $47.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2018-01-01 to 2018-06-30 | $5.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2018-06-30 | $309.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $899.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $1.53bn | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $202.5m | us-gaap:LiabilitiesCurrent |
Source: SEC EDGAR, the filing index for accession 0000883984-18-000025. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.